Myriad Genetics, Inc. Overview
Pro stress-test →Myriad Genetics is an American molecular diagnostic testing and precision medicine company based in Salt Lake City that offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. The company employs proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and guide development of products assessing disease risk, drug response, and disease progression.
Strategic Profile
Pro stress-test →Management is focused on the Cancer Care Continuum strategy, aiming to capture more revenue per patient by offering a suite of tests from risk assessment to therapy selection and prognosis, designed to increase test utilization and reduce reliance on any single product. Hereditary cancer testing showed particularly strong momentum with 10% volume growth for full year 2025 and 12% in Q4, while mental health testing volumes grew 6% for the year despite headwinds from payer policy changes.
Competitive Landscape
Pro stress-test →Myriad maintains a license collaboration with Illumina, Inc. Major competitors in genetic testing include Guardant Health (liquid biopsy), Veracyte (molecular diagnostics), Natera (reproductive and oncology testing), NeoGenomics (cancer diagnostics), and Qiagen (molecular diagnostics). Myriad's competitive advantage derives from its established market position in hereditary cancer testing and expanding Cancer Care Continuum strategy, though it faces pricing pressure from payers and competition from larger diagnostics firms.
Industry Context
Myriad Genetics, Inc. operates in Molecular Diagnostic Testing & Precision Medicine.
Key facts
Founded: 1991 · Headquarters: Salt Lake City, United States · Employees: 2,700 · Revenue: $824.5M · Market cap: $497.8M